MARKER THERAPEUTICS, INC. Research and Development Expense
MARKER THERAPEUTICS, INC. (MRKR) reported Research and Development Expense of $1.48 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-14
- MARKER THERAPEUTICS, INC. research and development expense for the quarter ending 2026-06-30 was $1.48M, a 64.66% decline year-over-year.
- MARKER THERAPEUTICS, INC. research and development expense for the quarter ending 2026-03-31 was $2.84M, a 9.34% decline year-over-year.
- MARKER THERAPEUTICS, INC. research and development expense for the quarter ending 2025-12-31 was $2.14M, a 57.91% decline year-over-year.
- MARKER THERAPEUTICS, INC. research and development expense for the quarter ending 2025-09-30 was $2.35M, a 32.42% decline year-over-year.
- MARKER THERAPEUTICS, INC. research and development expense for fiscal 2025 was $11.80M, a 12.39% decline from fiscal 2024.
- MARKER THERAPEUTICS, INC. research and development expense for fiscal 2024 was $13.47M, a 29.29% increase from fiscal 2023.
- MARKER THERAPEUTICS, INC. research and development expense for fiscal 2023 was $10.42M, a 12.96% decline from fiscal 2022.
- MARKER THERAPEUTICS, INC. research and development expense for fiscal 2022 was $11.97M, a 56.94% decline from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed | Research and Development Expense 143 month | Research and Development Expense 146 month | Research and Development Expense 149 month | Research and Development Expense 152 month | Research and Development Expense 155 month | Research and Development Expense 158 month | Research and Development Expense 161 month | Research and Development Expense 164 month | Research and Development Expense 164 month as first filed | Research and Development Expense 167 month | Research and Development Expense 170 month | Research and Development Expense 173 month | Research and Development Expense 173 month as first filed | Research and Development Expense 179 month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.48M 10-Q · filed 2026-08-14 | $4.32M 10-Q · filed 2026-08-14 | $6.46M derived: sum of 3 quarters · filed 2026-08-14 | $8.81M derived: sum of 4 quarters · filed 2026-08-14 | ||||||||||||||||||
| 2026-03-31 | $2.84M 10-Q · filed 2026-05-15 | $4.98M derived: sum of 2 quarters · filed 2026-05-15 | $7.33M derived: sum of 3 quarters · filed 2026-05-15 | $11.51M derived: sum of 4 quarters · filed 2026-08-14 | ||||||||||||||||||
| 2025-12-31 | $2.14M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $4.49M derived: sum of 2 quarters · filed 2026-03-18 | $8.66M derived: sum of 3 quarters · filed 2026-08-14 | $11.80M 10-K · filed 2026-03-18 | ||||||||||||||||||
| 2025-09-30 | $2.35M 10-Q · filed 2025-11-13 | $6.52M derived: sum of 2 quarters · filed 2026-08-14 | $9.66M 10-Q · filed 2025-11-13 | $14.74M derived: sum of 4 quarters · filed 2026-08-14 | ||||||||||||||||||
| 2025-06-30 | $4.18M 10-Q · filed 2026-08-14 | $7.31M 10-Q · filed 2026-08-14 | $12.40M derived: sum of 3 quarters · filed 2026-08-14 | $15.87M derived: sum of 4 quarters · filed 2026-08-14 | ||||||||||||||||||
| 2025-03-31 | $3.14M 10-Q · filed 2026-05-15 | $8.22M derived: sum of 2 quarters · filed 2026-05-15 | $11.69M derived: sum of 3 quarters · filed 2026-05-15 | $14.03M derived: sum of 4 quarters · filed 2026-05-15 | ||||||||||||||||||
| 2024-12-31 | $5.09M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $8.56M derived: sum of 2 quarters · filed 2026-03-18 | $10.89M derived: sum of 3 quarters · filed 2026-03-18 | $13.47M 10-K · filed 2026-03-18 | ||||||||||||||||||
| 2024-09-30 | $3.47M 10-Q · filed 2025-11-13 | $5.81M derived: sum of 2 quarters · filed 2025-11-13 | $8.38M 10-Q · filed 2025-11-13 | $11.00M derived: sum of 4 quarters · filed 2025-11-13 | ||||||||||||||||||
| 2024-06-30 | $2.34M 10-Q · filed 2025-08-14 | $4.91M 10-Q · filed 2025-08-14 | $7.53M derived: sum of 3 quarters · filed 2025-08-14 | $9.57M derived: sum of 4 quarters · filed 2025-08-14 | ||||||||||||||||||
| 2024-03-31 | $2.58M 10-Q · filed 2025-05-15 | $5.19M derived: sum of 2 quarters · filed 2025-05-15 | $7.24M derived: sum of 3 quarters · filed 2025-05-15 | $9.62M derived: sum of 4 quarters · filed 2025-05-15 | ||||||||||||||||||
| 2023-12-31 | $2.62M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $4.66M derived: sum of 2 quarters · filed 2025-03-31 | $7.04M derived: sum of 3 quarters · filed 2025-03-31 | $10.42M 10-K · filed 2025-03-31 | ||||||||||||||||||
| 2023-09-30 | $2.04M 10-Q · filed 2024-11-14 | $4.42M derived: sum of 2 quarters · filed 2024-11-14 | $7.80M 10-Q · filed 2024-11-14 | $9.98M derived: sum of 4 quarters · filed 2024-11-14 | ||||||||||||||||||
| 2023-06-30 | $2.38M 10-Q · filed 2024-08-14 | $5.75M 10-Q · filed 2024-08-14 | $7.94M derived: sum of 3 quarters · filed 2024-08-14 | $11.53M derived: sum of 4 quarters · filed 2024-08-14 | ||||||||||||||||||
| 2023-03-31 | $3.38M 10-Q · filed 2024-05-15 | $7.27M 10-Q · filed 2023-05-15 | $5.56M derived: sum of 2 quarters · filed 2024-05-15 | $9.15M derived: sum of 3 quarters · filed 2024-05-15 | $12.07M derived: sum of 4 quarters · filed 2024-05-15 | |||||||||||||||||
| 2022-12-31 | $2.18M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | $5.77M derived: sum of 2 quarters · filed 2024-03-26 | $8.70M derived: sum of 3 quarters · filed 2024-03-26 | $11.97M 10-K · filed 2024-03-26 | $26.14M 10-K · filed 2023-03-22 | |||||||||||||||||
| 2022-09-30 | $3.59M 10-Q · filed 2023-11-09 | $7.29M 10-Q · filed 2022-11-10 | $6.52M derived: sum of 2 quarters · filed 2023-11-09 | $9.79M 10-Q · filed 2023-11-09 | $20.87M 10-Q · filed 2022-11-10 | $21.56M derived: sum of 4 quarters · filed 2023-11-09 | ||||||||||||||||
| 2022-06-30 | $2.92M 10-Q · filed 2023-08-14 | $6.56M 10-Q · filed 2022-08-11 | $6.19M 10-Q · filed 2023-08-14 | $13.58M 10-Q · filed 2022-08-11 | $17.97M derived: sum of 3 quarters · filed 2023-08-14 | $24.75M derived: sum of 4 quarters · filed 2023-08-14 | ||||||||||||||||
| 2022-03-31 | $7.03M 10-Q · filed 2023-05-15 | $15.04M derived: sum of 2 quarters · filed 2023-05-15 | $21.83M derived: sum of 3 quarters · filed 2023-05-15 | $29.18M derived: sum of 4 quarters · filed 2023-05-15 | ||||||||||||||||||
| 2021-12-31 | $8.02M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22 | $14.80M derived: sum of 2 quarters · filed 2023-03-22 | $22.15M derived: sum of 3 quarters · filed 2023-03-22 | $27.79M 10-K · filed 2023-03-22 | ||||||||||||||||||
| 2021-09-30 | $6.78M 10-Q · filed 2022-11-10 | $14.13M derived: sum of 2 quarters · filed 2022-11-10 | $19.78M 10-Q · filed 2022-11-10 | $25.76M derived: sum of 4 quarters · filed 2022-11-10 | ||||||||||||||||||
| 2021-06-30 | $7.35M 10-Q · filed 2022-08-11 | $12.99M 10-Q · filed 2022-08-11 | $18.98M derived: sum of 3 quarters · filed 2022-08-11 | $23.78M derived: sum of 4 quarters · filed 2022-08-11 | ||||||||||||||||||
| 2021-03-31 | $5.64M 10-Q · filed 2022-05-13 | $11.63M derived: sum of 2 quarters · filed 2022-05-13 | $16.43M derived: sum of 3 quarters · filed 2022-05-13 | $20.71M derived: sum of 4 quarters · filed 2022-05-13 | ||||||||||||||||||
| 2020-12-31 | $5.98M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $10.79M derived: sum of 2 quarters · filed 2022-03-17 | $15.06M derived: sum of 3 quarters · filed 2022-03-17 | $18.88M 10-K · filed 2022-03-17 | ||||||||||||||||||
| 2020-09-30 | $4.80M 10-Q · filed 2021-11-10 | $9.08M derived: sum of 2 quarters · filed 2021-11-10 | $12.90M 10-Q · filed 2021-11-10 | $16.56M derived: sum of 4 quarters · filed 2021-11-10 | ||||||||||||||||||
| 2020-06-30 | $4.28M 10-Q · filed 2021-08-10 | $8.09M 10-Q · filed 2021-08-10 | $11.75M derived: sum of 3 quarters · filed 2021-08-10 | $14.87M derived: sum of 4 quarters · filed 2021-08-10 | ||||||||||||||||||
| 2020-03-31 | $3.82M 10-Q · filed 2021-05-12 | $7.48M derived: sum of 2 quarters · filed 2021-05-12 | $10.60M derived: sum of 3 quarters · filed 2021-05-12 | $13.75M derived: sum of 4 quarters · filed 2021-05-12 | ||||||||||||||||||
| 2019-12-31 | $3.66M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-09 | $6.78M derived: sum of 2 quarters · filed 2021-03-09 | $9.93M derived: sum of 3 quarters · filed 2021-03-09 | $12.76M 10-K · filed 2021-03-09 | ||||||||||||||||||
| 2019-09-30 | $3.12M 10-Q · filed 2020-11-09 | $6.27M derived: sum of 2 quarters · filed 2020-11-09 | $9.10M 10-Q · filed 2020-11-09 | $11.75M derived: sum of 4 quarters · filed 2020-11-09 | ||||||||||||||||||
| 2019-06-30 | $3.15M 10-Q · filed 2020-08-10 | $5.99M 10-Q · filed 2020-08-10 | $8.63M derived: sum of 3 quarters · filed 2020-08-10 | $10.51M derived: sum of 4 quarters · filed 2020-08-10 | ||||||||||||||||||
| 2019-03-31 | $2.83M 10-Q · filed 2020-05-11 | $5.48M derived: sum of 2 quarters · filed 2020-05-11 | $7.36M derived: sum of 3 quarters · filed 2020-05-11 | $9.19M derived: sum of 4 quarters · filed 2020-05-11 | ||||||||||||||||||
| 2018-12-31 | $2.65M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $4.53M derived: sum of 2 quarters · filed 2020-03-12 | $6.35M derived: sum of 3 quarters · filed 2020-03-12 | $7.95M 10-K · filed 2020-03-12 | ||||||||||||||||||
| 2018-09-30 | $1.88M 10-Q · filed 2019-11-12 | $3.70M derived: sum of 2 quarters · filed 2019-11-12 | $5.30M 10-Q · filed 2019-11-12 | $6.74M derived: sum of 4 quarters · filed 2019-11-12 | ||||||||||||||||||
| 2018-06-30 | $1.83M 10-Q · filed 2019-08-09 | $3.43M 10-Q · filed 2019-08-09 | $4.86M derived: sum of 3 quarters · filed 2019-08-09 | $6.49M derived: sum of 4 quarters · filed 2019-08-09 | ||||||||||||||||||
| 2018-03-31 | $1.60M 10-Q · filed 2019-05-10 | $3.04M derived: sum of 2 quarters · filed 2019-05-10 | $4.66M derived: sum of 3 quarters · filed 2019-05-10 | $5.86M derived: sum of 4 quarters · filed 2019-05-10 | ||||||||||||||||||
| 2017-12-31 | $1.44M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-15 | $3.06M derived: sum of 2 quarters · filed 2019-03-15 | $4.26M derived: sum of 3 quarters · filed 2019-03-15 | $5.25M 10-K · filed 2019-03-15 | ||||||||||||||||||
| 2017-09-30 | $1.62M 10-Q · filed 2018-11-13 | $2.83M derived: sum of 2 quarters · filed 2018-11-13 | $3.82M 10-Q · filed 2018-11-13 | $4.27M derived: sum of 4 quarters · filed 2018-11-13 | ||||||||||||||||||
| 2017-06-30 | $1.20M 10-Q · filed 2018-08-09 | $2.19M 10-Q · filed 2018-08-09 | $2.65M derived: sum of 3 quarters · filed 2018-08-09 | $3.76M derived: sum of 4 quarters · filed 2018-08-09 | ||||||||||||||||||
| 2017-03-31 | $989.09K 10-Q · filed 2018-05-15 | $1.45M derived: sum of 2 quarters · filed 2018-05-15 | $2.56M derived: sum of 3 quarters · filed 2018-05-15 | $3.80M derived: sum of 4 quarters · filed 2018-05-15 | ||||||||||||||||||
| 2016-12-31 | $456.79K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-23 | $1.57M derived: sum of 2 quarters · filed 2018-03-23 | $2.81M derived: sum of 3 quarters · filed 2018-03-23 | $3.80M 10-K · filed 2018-03-23 | ||||||||||||||||||
| 2016-09-30 | $1.11M 10-Q · filed 2017-11-14 | $2.36M derived: sum of 2 quarters · filed 2017-11-14 | $3.34M 10-Q · filed 2017-11-14 | $2.73M derived: sum of 4 quarters · filed 2017-11-14 | ||||||||||||||||||
| 2016-06-30 | $1.25M 10-Q · filed 2017-08-07 | $2.23M 10-Q · filed 2017-08-07 | $1.62M derived: sum of 3 quarters · filed 2017-08-07 | $2.59M derived: sum of 4 quarters · filed 2017-08-07 | ||||||||||||||||||
| 2016-03-31 | $985.75K 10-Q · filed 2017-05-05 | $372.50K derived: sum of 2 quarters · filed 2017-05-05 | $1.34M derived: sum of 3 quarters · filed 2017-05-05 | $1.54M derived: sum of 4 quarters · filed 2017-05-05 | ||||||||||||||||||
| 2015-12-31 | -$613.25K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-14 | $355.50K derived: sum of 2 quarters · filed 2017-03-14 | $556.66K derived: sum of 3 quarters · filed 2017-03-14 | $1.71M 10-K · filed 2017-03-14 | ||||||||||||||||||
| 2015-09-30 | $968.76K 10-Q · filed 2016-11-04 | $769.22K 10-Q · filed 2015-11-16 | $1.17M derived: sum of 2 quarters · filed 2016-11-04 | $2.32M 10-Q · filed 2016-11-04 | $1.58M 10-Q · filed 2015-11-16 | $1.89M derived: sum of 4 quarters · filed 2016-11-04 | ||||||||||||||||
| 2015-06-30 | $201.16K 10-Q · filed 2016-08-15 | $810.53K 10-Q · filed 2016-08-15 | $922.03K derived: sum of 3 quarters · filed 2016-08-15 | $954.53K derived: sum of 4 quarters · filed 2016-08-15 | ||||||||||||||||||
| 2015-03-31 | $609.38K 10-Q · filed 2016-05-16 | $720.88K derived: sum of 2 quarters · filed 2016-05-16 | $753.38K derived: sum of 3 quarters · filed 2016-05-16 | $775.88K derived: sum of 4 quarters · filed 2016-05-16 | ||||||||||||||||||
| 2014-12-31 | $111.50K derived: 10-K 12 month − 10-Q/A 9 month · filed 2016-04-14 | $144.00K derived: sum of 2 quarters · filed 2016-04-14 | $166.50K derived: sum of 3 quarters · filed 2016-04-14 | $189.00K 10-K · filed 2016-04-14 | ||||||||||||||||||
| 2014-09-30 | $32.50K 10-Q/A · filed 2016-04-14 | $55.00K derived: sum of 2 quarters · filed 2016-04-14 | $77.50K 10-Q/A · filed 2016-04-14 | $556.36K derived: sum of 4 quarters · filed 2016-04-14 | ||||||||||||||||||
| 2014-06-30 | $22.50K 10-Q/A · filed 2016-04-14 | $45.00K 10-Q/A · filed 2016-04-14 | $523.86K derived: sum of 3 quarters · filed 2016-04-14 | $553.86K derived: sum of 4 quarters · filed 2016-04-14 | $7.68M 10-Q · filed 2014-08-18 | |||||||||||||||||
| 2014-03-31 | $22.50K 10-Q/A · filed 2016-04-14 | $501.36K derived: sum of 2 quarters · filed 2016-04-14 | $531.36K derived: sum of 3 quarters · filed 2016-04-14 | $585.75K derived: sum of 4 quarters · filed 2016-04-14 | ||||||||||||||||||
| 2013-12-31 | $478.86K derived: 10-K 12 month − 10-Q 9 month · filed 2015-04-15 | $508.86K derived: sum of 2 quarters · filed 2015-04-15 | $563.25K derived: sum of 3 quarters · filed 2015-04-15 | $661.63K 10-K/A · filed 2014-04-17 | $7.65M 10-Q/A · filed 2014-05-21 | $7.60M 10-K/A · filed 2014-04-17 | ||||||||||||||||
| 2013-09-30 | $30.00K 10-Q · filed 2014-11-19 | $84.40K derived: sum of 2 quarters · filed 2014-11-19 | $218.78K 10-Q · filed 2014-11-19 | $843.92K derived: sum of 4 quarters · filed 2014-11-19 | $7.19M 10-Q · filed 2013-11-19 | |||||||||||||||||
| 2013-06-30 | $54.40K 10-Q · filed 2014-08-18 | $188.78K 10-Q · filed 2014-08-18 | $813.92K derived: sum of 3 quarters · filed 2014-08-18 | $884.98K derived: sum of 4 quarters · filed 2014-08-18 | $7.16M 10-Q · filed 2013-08-19 | |||||||||||||||||
| 2013-03-31 | $134.38K 10-Q/A · filed 2014-05-21 | $242.98K 10-Q · filed 2013-05-21 | $759.52K derived: sum of 2 quarters · filed 2014-05-21 | $830.58K derived: sum of 3 quarters · filed 2014-05-21 | $1.08M derived: sum of 4 quarters · filed 2014-05-21 | $7.10M 10-Q/A · filed 2013-08-19 | $7.21M 10-Q · filed 2013-05-21 | |||||||||||||||
| 2012-12-31 | $625.14K derived: 10-K 12 month − 10-Q 9 month · filed 2013-05-15 | $696.20K derived: sum of 2 quarters · filed 2013-11-19 | $941.97K derived: sum of 3 quarters · filed 2013-11-19 | $1.06M 10-K/A · filed 2014-04-17 | $6.97M 10-K · filed 2013-05-15 | |||||||||||||||||
| 2012-09-30 | $71.06K 10-Q · filed 2013-11-19 | $316.82K derived: sum of 2 quarters · filed 2013-11-19 | $432.29K 10-Q · filed 2013-11-19 | $229.07K derived: sum of 4 quarters · filed 2013-11-19 | $6.34M 10-Q · filed 2012-11-19 | |||||||||||||||||
| 2012-06-30 | $245.76K 10-Q · filed 2013-08-19 | $145.76K 10-Q/A · filed 2012-09-12 | $361.23K 10-Q · filed 2013-08-19 | $261.23K 10-Q/A · filed 2012-09-12 | $158.01K derived: sum of 3 quarters · filed 2013-08-19 | $456.00K derived: sum of 4 quarters · filed 2013-08-19 | $6.17M 10-Q/A · filed 2012-09-12 | |||||||||||||||
| 2012-03-31 | $115.47K 10-Q/A · filed 2013-08-19 | -$87.75K derived: sum of 2 quarters · filed 2013-08-19 | $210.24K derived: sum of 3 quarters · filed 2013-08-19 | $267.77K derived: sum of 4 quarters · filed 2013-08-19 | $6.03M 10-Q · filed 2012-05-21 | |||||||||||||||||
| 2011-12-31 | -$203.22K derived: 10-K 12 month − 10-Q 9 month · filed 2013-05-15 | $94.78K derived: sum of 2 quarters · filed 2013-05-15 | $152.30K derived: sum of 3 quarters · filed 2013-05-15 | $203.72K 10-K · filed 2013-05-15 | $5.91M 10-K · filed 2012-04-16 | |||||||||||||||||
| 2011-09-30 | $298.00K 10-Q · filed 2012-11-19 | $355.52K derived: sum of 2 quarters · filed 2012-11-19 | $406.94K 10-Q · filed 2012-11-19 | $453.61K derived: sum of 4 quarters · filed 2012-11-19 | $6.11M 10-Q · filed 2011-11-21 | |||||||||||||||||
| 2011-06-30 | $57.53K 10-Q/A · filed 2012-09-12 | $108.95K 10-Q/A · filed 2012-09-12 | $155.62K derived: sum of 3 quarters · filed 2012-09-12 | $249.13K derived: sum of 4 quarters · filed 2012-09-12 | $5.82M 10-Q · filed 2011-08-22 | |||||||||||||||||
| 2011-03-31 | $51.42K 10-Q · filed 2012-05-21 | $98.09K derived: sum of 2 quarters · filed 2012-05-21 | $191.61K derived: sum of 3 quarters · filed 2012-05-21 | $298.20K derived: sum of 4 quarters · filed 2012-05-21 | ||||||||||||||||||
| 2010-12-31 | $46.67K derived: 10-K 12 month − 10-Q 9 month · filed 2012-04-16 | $140.19K derived: sum of 2 quarters · filed 2012-04-16 | $246.78K derived: sum of 3 quarters · filed 2012-04-16 | $290.05K 10-K · filed 2012-04-16 | ||||||||||||||||||
| 2010-09-30 | $93.52K 10-Q · filed 2011-11-21 | $200.11K derived: sum of 2 quarters · filed 2011-11-21 | $243.38K 10-Q · filed 2011-11-21 | |||||||||||||||||||
| 2010-06-30 | $106.59K 10-Q · filed 2011-08-22 | $149.86K 10-Q · filed 2011-08-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |